Stock MIST MILESTONE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
1.38 USD -0.72% Intraday chart for Milestone Pharmaceuticals Inc. -2.13% -17.37%
06-20 Transcript : Milestone Pharmaceuticals Inc. - Special Call
05-29 Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST?
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt
MÄRKTE USA/Wall Street mit moderater Weihnachtsrally - Intel gesucht
Milestone Pharmaceuticals Says FDA Issued Refusal-to-File Letter for New Drug Application for Etripamil; Shares Fall Pre-Bell
Top Premarket Decliners
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Alta Advisers Sends a Letter to Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Top Premarket Decliners
Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIST Stock
  4. News Milestone Pharmaceuticals Inc.
  5. Other languages